1-3 of 3
antigens, cd27
Close
Sort by
Journal Articles

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

Stephen M. Ansell, Ian Flinn, Matthew H. Taylor, Branimir I. Sikic, Joshua Brody, John Nemunaitis, Andrew Feldman, Thomas R. Hawthorne, Tracey Rawls, Tibor Keler, Michael J. Yellin
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1917–1926.
https://doi.org/10.1182/bloodadvances.2019001079
Published: 2020
Includes: Supplemental data
Journal Articles

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists

Christopher T. Petersen, Mojibade Hassan, Anna B. Morris, Jasmin Jeffery, Kunhee Lee, Neera Jagirdar, Ashley D. Staton, Sunil S. Raikar, Harold T. Spencer, Todd Sulchek, Christopher R. Flowers, Edmund K. Waller
Journal: Blood Advances
Blood Adv (2018) 2 (3): 210–223.
https://doi.org/10.1182/bloodadvances.2017011254
Published: 2018
Includes: Supplemental data
Journal Articles

Macrophages and osteoclasts stem from a bipotent progenitor downstream of a macrophage/osteoclast/dendritic cell progenitor

Yanling Xiao, Jara Palomero, Joanna Grabowska, Liqin Wang, Iris de Rink, Luuk van Helvert, Jannie Borst
Journal: Blood Advances
Blood Adv (2017) 1 (23): 1993–2006.
https://doi.org/10.1182/bloodadvances.2017008540
Published: 2017
Includes: Supplemental data